

2. (g) It would appear to be advisable to hear from a general practitioner, or practitioners, about the impact of all these various methods of drug promotion on the practice of medicine and whether he or they would have any comment to make on present-day practices in so far as they may effect the safe administration of drugs.

A practicing physician or physicians appointed by the Canadian Medical Association.

2. (h) The committee should investigate ways and means of informing the public of the misuse of drugs in the home; for example, making sure that drugs are out of the reach of children; cleaning out medicine cabinets regularly and so on.

Mrs. A. F. W. Plumtre, President, Canadian Association of Consumers, Ottawa.

Information officers of the Department of Health and Welfare should be called.

3. The Chairman of the special committee of the Royal College of Physicians and Surgeons should be called to present to the committee the recommendations in that committee's report. They should inform the committee the reasons for the recommendations which have been made and be expected to answer questions. They will probably require other members of the committee to assist him in answering questions.

Terms of reference of this committee are:

To examine critically and objectively our present procedures for dealing with new drugs, the requirements of the regulations, and any other matters that, in the opinion of the committee, are relative to the issue. I should point out that the purpose of the new drug regulations is to ensure safety.

Dr. F. S. Brien, Chairman

Dr. E. A. Sellars and Dr. R. Dufresne.

4. In order for the committee to have a better idea of how the sale and marketing of drugs are controlled in other countries, it would be advisable to have someone appear before the committee and outline some of the regulations which are in effect in various countries. The World Health Organization has a unit which deals with standards for pharmaceuticals. The head of the unit should be able to provide the committee with details on existing legislation in various countries and be able to give a limited appraisal of existing legislation.

Mr. Paul Blanc, World Health Organization, Geneva, Switzerland.

The next section of the proposal is a list of professional people, professional associations and individuals that might be called. I do not have the list of manufacturers because the list is as long as your arm and I think we can trust the subcommittee to bring proper proposals before this committee in respect of this aspect. If you like I will go through the list of witnesses that we propose calling for your consideration in these terms and their qualifications or shall I just take it as read?

I think perhaps I should go over them. They are: Dr. A. D. Kelly, General Secretary, The Canadian Medical Association, 150 St. George Street, Toronto 5, Ontario; Mr. J. C. Turnbull, Secretary-Manager, The Canadian Pharmaceutical Association, 221 Victoria Street, Toronto, Ontario; Dr. E. W. Bensley, Secretary, The Pharmacological Society of Canada, Montreal General Hospital, 1650 Cedar Avenue, Montreal, Quebec; Dr. John C. Laidlaw, President, The Canadian Society for Clinical Investigation, 36 Hudson Drive, Toronto, Ontario; Dr. W. W. Tidmarsh, Secretary, The Canadian Paediatric Society, 79 Percival